Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
GSK (GSK) announced the U.S. Food and Drug Administration (FDA) has approved Blenrep in combination with bortezomib and dexamethasone for the ...
GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study GMMG-HD7 is an open-label, randomized, multicenter, ...
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs ...
BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of ...
London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback